Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3828983 | 0.92 | KDM4E (0.42) | KDM4EMAPK1NPSR1LMNASRC | |
| SCHEMBL25332124 | 0.87 | SRC (0.45) | KDM4ESRCALDH1A1F2GLA | |
| SCHEMBL440060 | 0.81 | BCHE (0.50) | KDM4ENPSR1LMNASRCMAPT | |
| SCHEMBL5185398 | 0.81 | SRC (0.45) | KDM4EMAPK1NPSR1LMNASRC | |
| SCHEMBL29923658 | 0.81 | SRC (0.45) | KDM4EMAPK1NPSR1LMNASRC | |
| SCHEMBL2998324 | 0.81 | SRC (0.45) | KDM4EMAPK1NPSR1LMNASRC | |
| SCHEMBL13652292 | 0.81 | LMNA (0.47) | KDM4EMAPK1NPSR1LMNAALDH1A1 | |
| SCHEMBL6080573 | 0.81 | LMNA (0.47) | KDM4EMAPK1NPSR1LMNAALDH1A1 | |
| SCHEMBL2313075 | 0.79 | LMNA (0.56) | KDM4EMAPK1NPSR1LMNASRC | |
| SCHEMBL14400286 | 0.78 | KDM4E (0.48) | KDM4ELMNASRCALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1695964-A1 | Quinoline derivatives for use as intermediates in the synthesis of heterocyclylalcoyl piperidines | NOVEXEL (FR) | 2006-08-30 | — | — | EP | claimed |
| EP-2181996-A1 | Aminopiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2010-05-05 | — | — | EP | disclosed |
| US-7691850-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| EP-1796466-A4 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2009-09-02 | — | — | EP | disclosed |
| US-20090131444-A1 | Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| CN-101258157-A | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity | ASTRAZENECA AB (SE) | 2008-09-03 | — | — | CN | disclosed |
| EP-1891078-A1 | AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| US-7312212-B2 | Aminopiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2007-12-25 | — | — | US | disclosed |
| US-20070287701-A1 | 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | SMITHKLINE BEECHAM CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20070244103-A1 | Novel Compounds Having an Anti-Bacterial Activity | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2007-10-18 | — | — | US | disclosed |
| US-6903217-B2 | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them | AVENTIS PHARMA S.A. (FR) | 2005-06-07 | — | — | US | disclosed |
| EP-1470125-A1 | AMINOPIPERIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2004-10-27 | — | — | EP | disclosed |
| US-20040147518-A1 | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them | AVENTIS PHARMA S.A. | 2004-07-29 | — | — | US | disclosed |
| WO-2004058144-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2004-07-15 | — | — | WO | disclosed |
| CN-1483031-A | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them | ���ĵ�˹ҩ��ɷ�����˾ | 2004-03-17 | — | — | CN | disclosed |
| EP-1337529-A2 | HETEROCYCLYLALKYL PIPERIDINE DERIVATIVES, THEIR PREPARATION AND COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2003-08-27 | — | — | EP | disclosed |
| WO-2003064421-A1 | AMINOPIPERIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-08-07 | — | — | WO | disclosed |
| US-6603005-B2 | Bactericides | AVENTIS PHARMA S.A. (FR) | 2003-08-05 | — | — | US | disclosed |
| US-20020111492-A1 | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them | NOVEXEL (FR) | 2002-08-15 | — | — | US | disclosed |
| WO-2002040474-A2 | HETEROCYCLYLALKYL PIPERIDINE DERIVATIVES AND THEIR USE AS ANTIMICROBIAL AGENTS | AVENTIS PHARMA S.A. (FR) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147518-A1 | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them | SYNJ1, NCAPD2, SYNJ2 | KDM4E 4252/4885MAPK1 659/4885NPSR1 2219/4885 |
| US-20070287701-A1 | 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | NPM1, TOP1, HMGB1 | KDM4E 1115/4885MAPK1 1060/4885NPSR1 2323/4885 |
| US-20020111492-A1 | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them | SYNJ1, NCAPD2, SYNJ2 | KDM4E 4252/4885MAPK1 659/4885NPSR1 2219/4885 |
| US-20090131444-A1 | Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity | AAAS, AMPD2, AMPD3 | KDM4E 552/4885MAPK1 3309/4885NPSR1 4014/4885 |
| US-20070244103-A1 | Novel Compounds Having an Anti-Bacterial Activity | TOP1, TOP2A, TOP2B | KDM4E 2755/4885MAPK1 2275/4885NPSR1 4170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.